Note we may have some server downtime today and this weekend as we perform some upgrades. Please save a copy of any posts you make during this time in case we have any server trouble. Thank you!
I'm pretty sure he told me his full name in an old PM. I'll try to find it and see if I can find a phone number for him.gwa wrote:Dom is bedridden and doesn't go out for vacations. I am worried about him too and also P/M'd him and got no response.
Hi robbie,robbie wrote:Do you think Bob that with RRMS it is eaiser for companies to get better results because of the natural remission of attacks drugs or not.
Second Patient With Multiple Sclerosis Undergoes Groundbreaking Surgery At Yale
Science Daily — New Haven, Conn. A 29-year-old man with multiple sclerosis is the second patient to undergo transplantation surgery at Yale in an effort to repair myelin, the protective brain and spinal cord sheath that is destroyed by the disease, Yale researchers have reported. The surgery took place in two stages March 6-7 and the patient was discharged from Yale-New Haven Hospital March 10. The young man is the second of five patients who are scheduled to participate in the groundbreaking clinical trial.
Vollmer said he and his team hope to perform the procedure on a third patient next month.
The purpose of the Phase One trial is to determine whether cells found in the body's peripheral nerves, in this case, the ankle, can safely repair the damaged cells in the brain and spinal cord that result in neurologic disability in patients with multiple sclerosis and other disorders of myelin.
In the first procedure on March 6, the surgical team harvested Schwann cells from the patient's ankle. Animal studies show that Schwann cells can replace the cells that generate the myelin. The second day, the cells were injected into the left posterior aspect of the patient's brain, which has lesions.
Vollmer said he and his team want to determine whether the Schwann cells survive in the brain and if they are able to restore myelin on the nerve fibers in the brain. The patient's progress is then monitored for six months using neuroimaging and other tests. After six months a small biopsy is taken to determine whether the cells survived and whether they made any myelin.
The six month results on the first patient will not be made public until they are published in a peer-reviewed medical journal.
Vollmer's team includes Jeffrey Kocsis, Dennis Spencer, M.D., Stephen Waxman, M.D., Adam Anderson, John Gore and others. The research is fully funded by The Myelin Project in Washington, D.C.
Thanks Cure.CureOrBust wrote: In this case, I took no news as bad news. I searched google scholar for the Dr's names, and they have published many articles since on rat studies.
As expected from previous work, Schwann cell implants survive poorly unless the cells find axons to myelinate, the cells do not migrate significantly from the implantation site, fail to integrate with host oligodendrocytes and astrocytes, and form little myelin when challenged with astrocyte-rich environment in the retina.
dignan wrote: As expected from previous work, Schwann cell implants survive poorly unless the cells find axons to myelinate, the cells do not migrate significantly from the implantation site, fail to integrate with host oligodendrocytes and astrocytes, and form little myelin when challenged with astrocyte-rich environment in the retina.
thyroid hormone enhances and accelerates remyelination in an experimental model of chronic demyelination
Thyroid hormone, when administered during the acute phase of the disease, increases expression of platelet-derived growth factor alpha receptor, restores normal levels of myelin basic protein mRNA and protein, and allows an early and morphologically competent reassembly of myelin sheaths. Moreover, thyroid hormone exerts a neuroprotective effect with respect to axonal pathology.
In addition to its traditional role in reproduction, progesterone (PROG) has demonstrated neuroprotective and promyelinating effects in lesions of the peripheral and central nervous systems, including the spinal cord.
PROG also promotes myelination in the brain, as shown in vitro in explant cultures of cerebellar slices and in vivo in the cerebellar peduncle of aged rats after toxin-induced demyelination.
Local synthesis of PROG in the brain and the neuroprotective and promyelinating effects of this neurosteroid offer interesting therapeutic possibilities for the prevention and treatment of neurodegenerative diseases, for accelerating regenerative processes and for preserving cognitive functions during aging.
Both ovariectomized female and male animals treated with progesterone showed a profound reduction in axonal injury (seen via diminished APP immunoreactivity) when compared to controls.
Users browsing this forum: No registered users